Full text is available at the source.
Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance
Semaglutide treatment for fatty liver disease linked to metabolism: November 2025 AASLD guidance update
AI simplified
Abstract
The Wegovy® formulation containing semaglutide received accelerated FDA approval in August 2025 for treating Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) with moderate to advanced fibrosis.
- In the phase 3 ESSENCE trial, 72 weeks of semaglutide treatment resulted in a 62.9% resolution of MASH without worsening of fibrosis compared to 34.3% in the placebo group (p <0.001).
- The treatment also achieved a ≥1 stage reduction in liver fibrosis without worsening of MASH in 36.8% of patients versus 22.4% in the placebo group (p <0.001).
- Candidates for treatment should exhibit MASH with stage 2-3 fibrosis identified through noninvasive tests like VCTE, MRE, or ELF rather than liver biopsy.
- Semaglutide demonstrated a favorable safety profile, with no discontinuations due to liver enzyme elevations and common mild gastrointestinal adverse events.
- Monitoring for rare but serious risks such as acute kidney injury and pancreatitis is recommended for patients receiving semaglutide.
- Lifestyle modification is emphasized as a key component of management alongside semaglutide therapy.
AI simplified